GlassScriptPhysician profile
Ari Ben Hirsch
NPI 1396952594
$5,891.61
in general payments reported to CMS, 2019-2025
32 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $522 · 2021: $440 · 2022: $562 · 2023: $583 · 2024: $1,427 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.80 |
| Education | $208.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $943.78 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $492.33 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Vifor Pharma, INC. | $483.03 | 2019-2025 | Veltassa, Zemaira |
| Mallinckrodt Hospital Products INC. | $446.49 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $443.87 | 2019-2024 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $410.89 | 2019-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $391.65 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $257.76 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $254.82 | 2022-2025 | Filspari |
| Ardelyx, INC. | $219.75 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $217.79 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.05 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $149.86 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $132.11 | 2022-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $113.12 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $104.55 | 2019 | |
| Ani Pharmaceuticals, INC. | $86.36 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $76.21 | 2020-2023 | Benlysta |
| Novo Nordisk INC | $72.23 | 2023-2025 | Rybelsus, Ozempic |
| Calliditas Therapeutics US INC. | $62.69 | 2022-2025 | Tarpeyo |
| Scpharmaceuticals INC. | $56.09 | 2025 | |
| Horizon Therapeutics Plc | $54.13 | 2022-2023 | Krystexxa |
| Baxter Healthcare | $51.96 | 2019-2023 | Renal - Pd |
| Cormedix INC. | $51.69 | 2024-2025 | Defencath, Defencath |
| Kyowa Kirin, INC. | $41.93 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $35.63 | 2024 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $18.01 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.83 | 2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $16.37 | 2022 | |
| Lilly USA, LLC | $15.41 | 2025 | |
| Abiomed | $14.25 | 2025 | |
| Biomerieux INC | $8.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.